Literature DB >> 6185041

In vivo and in vitro sensitivity of Falciparum malaria to quinine in Thai children.

T Chongsuphajaisiddhi, A Sabcharoen, P Attanath.   

Abstract

The study was carried out to assess the efficacy of quinine in children with Falciparum malaria in relation to in vitro sensitivity (measured in terms of minimum inhibitory concentration: MIC) and to trough serum levels of quinine during the course of treatment. Fifty children aged ten months to 12 years with Falciparum malaria were randomly divided into two groups. Group I: 24 children were treated with quinine 10 mg base per body weight every eight hours for 14 days. Group II: 26 children were treated with quinine at the dosage adjusted to the body surface area based on an adult dose of 500 mg base eight hourly for 14 days. There were three treatment failures, one RI and one RII in group I, and one RI in group II. The serum concentrations of quinine reached a peak level on day two and levelled off by the end of the first week. Concentrations in group II were higher than in group I. The mean minimal inhibitory concentration (MIC) of quinine in the two groups was 14.89 nmol per ml ranging from 8-26 nmol per ml. In cases with treatment failure, the trough serum quinine levels became lower than the corresponding MIC after day six (RI) and after day two (RII). The rise of MIC suggests that sensitivity of Falciparum malaria parasites to quinine may be decreasing in Thailand. Failures of treatment in standard dosage may occur in cases infected by parasites with high MIC, in which trough serum quinine levels cannot be maintained above the MIC longer than six days during the course of treatment. However in one cured case, the trough serum quinine levels were below the MIC throughout treatment. More research is needed on the real relationship between serum quinine concentrations, the MIC, and clinical and parasitological response to quinine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6185041     DOI: 10.1080/02724936.1981.11748054

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN: 0272-4936


  20 in total

Review 1.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

2.  The treatment of severe falciparum malaria.

Authors:  W Peters; A P Hall
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

3.  Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.

Authors:  T M Davis; J Karbwang; S Looareesuwan; R C Turner; N J White
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 4.  Resistance of Plasmodium falciparum.

Authors:  E B Doberstyn
Journal:  Experientia       Date:  1984-12-15

Review 5.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

6.  Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria.

Authors:  R E Phillips; S Looareesuwan; N J White; K Silamut; S Kietinun; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

7.  Susceptibility of Plasmodium falciparum to different doses of quinine in vivo and to quinine and quinidine in vitro in relation to chloroquine in Liberia.

Authors:  A Björkman; M Willcox; N Marbiah; D Payne
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

Review 8.  Antimalarial drugs. An update.

Authors:  D C Warhurst
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

9.  Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria.

Authors:  S Pukrittayakamee; S Wanwimolruk; K Stepniewska; A Jantra; S Huyakorn; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 10.  High first dose quinine regimen for treating severe malaria.

Authors:  A Lesi; M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.